Hanson & Doremus Investment Management Trims Stock Holdings in Baxter International Inc. $BAX

Hanson & Doremus Investment Management lowered its stake in Baxter International Inc. (NYSE:BAX) by 34.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 954 shares of the medical instruments supplier’s stock after selling 507 shares during the quarter. Hanson & Doremus Investment Management’s holdings in Baxter International were worth $29,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in BAX. Zions Bancorporation National Association UT bought a new stake in Baxter International during the 1st quarter worth approximately $27,000. Rossby Financial LCC purchased a new stake in shares of Baxter International in the first quarter worth $29,000. MassMutual Private Wealth & Trust FSB raised its position in shares of Baxter International by 48.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 2,021 shares of the medical instruments supplier’s stock valued at $69,000 after purchasing an additional 656 shares during the period. Archer Investment Corp lifted its stake in shares of Baxter International by 20.5% during the 1st quarter. Archer Investment Corp now owns 2,935 shares of the medical instruments supplier’s stock valued at $100,000 after buying an additional 500 shares in the last quarter. Finally, Bruce G. Allen Investments LLC boosted its holdings in Baxter International by 35.2% in the 1st quarter. Bruce G. Allen Investments LLC now owns 3,546 shares of the medical instruments supplier’s stock worth $121,000 after buying an additional 924 shares during the period. 90.19% of the stock is currently owned by institutional investors.

Baxter International Trading Up 1.7%

Shares of NYSE BAX opened at $22.36 on Tuesday. Baxter International Inc. has a 1-year low of $21.33 and a 1-year high of $38.28. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.30 and a quick ratio of 1.49. The business’s 50 day moving average is $24.30 and its two-hundred day moving average is $28.37. The stock has a market capitalization of $11.48 billion, a P/E ratio of -74.52, a PEG ratio of 0.72 and a beta of 0.61.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, July 31st. The medical instruments supplier reported $0.59 EPS for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.01). The company had revenue of $2.81 billion during the quarter, compared to analysts’ expectations of $2.82 billion. Baxter International had a positive return on equity of 16.96% and a negative net margin of 1.42%.Baxter International’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.68 EPS. Baxter International has set its Q3 2025 guidance at 0.580-0.620 EPS. FY 2025 guidance at 2.420-2.520 EPS. As a group, research analysts expect that Baxter International Inc. will post 2.48 EPS for the current year.

Baxter International Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 1st. Stockholders of record on Friday, August 29th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Friday, August 29th. This represents a $0.68 annualized dividend and a dividend yield of 3.0%. Baxter International’s dividend payout ratio is currently -226.67%.

Wall Street Analysts Forecast Growth

BAX has been the subject of a number of analyst reports. Wells Fargo & Company cut their price target on Baxter International from $33.00 to $24.00 and set an “equal weight” rating for the company in a research note on Friday, August 1st. Barclays cut their target price on Baxter International from $41.00 to $36.00 and set an “overweight” rating for the company in a research report on Monday, August 4th. Morgan Stanley lowered their price target on Baxter International from $28.00 to $27.00 and set an “underweight” rating on the stock in a report on Tuesday, July 15th. UBS Group cut their price objective on shares of Baxter International from $35.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, August 4th. Finally, Evercore ISI reduced their price objective on shares of Baxter International from $44.00 to $42.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Three investment analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Baxter International currently has a consensus rating of “Hold” and an average price target of $30.11.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.